Novaliq is a pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics. All first- and best-in-class ocular therapeutics are based on the patented EyeSol® technology.  EyeSol® is the first and only water-free technology that overcomes the limitations of water-free eyedrops, improving the topical bioavailability, stability, and safety of traditionally unstable pharmaceutical ingredients. Semifluorinated alkanes (SFAs) form the basis for EyeSol® - scientific know-how made in Germany. 

• Worldwide first water-free drug delivery technology (EyeSol®) overcoming limitations of water-based    eyedrops
• High product-development competence and integrated processes along the entire value-chain (from the development of the fomulation, the preclinical and clinical stages, all the way to the market)
• Industry-leading product pipeline for Dry Eye Disease based on several new mechanisms of action (MoAs)
• Significant platform value captured in extensive early stage pipeline in glaucoma and retinal diseases
• Intensive and integrative, academic cooperation in the therapeutic area